Evidence map›Paper›PMID 22519592›Full record

ArticleClinical and experimental immunology2012

Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantation.

G L V de Oliveira, K C R Malmegrim, A F Ferreira, R Tognon, S Kashima, C E B Couri, D T Covas, J C Voltarelli, F A de Castro

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Bone marrow transplantation reverses new-onset immunoinflammatory diabetes in a mouse model.International journal of clinical and experimental pathology · 2014
    Article
  15. Progress in immune-based therapies for type 1 diabetes.Clinical and experimental immunology · 2013
    Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

G L V de OliveiraSchool of Pharmaceutical Sciences, University of São Paulo, Department of Clinical Analysis, Ribeirão Preto, São Paulo, Brazil.
K C R Malmegrim
A F Ferreira
R Tognon
S Kashima
C E B Couri
D T Covas
J C Voltarelli
F A de Castro
Universidade de São Paulo · BRInstitute for Stem Cell Biology and Regenerative Medicine · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by T cell-mediated destruction of pancreatic β cells, resulting in insulin deficiency and hyperglycaemia. Recent studies have described that apoptosis impairment during central and peripheral tolerance is involved in T1D pathogenesis. In this study, the apoptosis-related gene expression in T1D patients was evaluated before and after treatment with high-dose immunosuppression followed by autologous haematopoietic stem cell transplantation (HDI-AHSCT). We also correlated gene expression results with clinical response to HDI-AHSCT. We observed a decreased expression of bad, bax and fasL pro-apoptotic genes and an increased expression of a1, bcl-x(L) and cIAP-2 anti-apoptotic genes in patients' peripheral blood mononuclear cells (PBMCs) compared to controls. After HDI-AHSCT, we found an up-regulation of fas and fasL and a down-regulation of anti-apoptotic bcl-x(L) genes expression in post-HDI-AHSCT periods compared to pre-transplantation. Additionally, the levels of bad, bax, bok, fasL, bcl-x(L) and cIAP-1 genes expression were found similar to controls 2 years after HDI-AHSCT. Furthermore, over-expression of pro-apoptotic noxa at 540 days post-HDI-AHSCT correlated positively with insulin-free patients and conversely with glutamic acid decarboxylase autoantibodies (GAD65) autoantibody levels. Taken together, the results suggest that apoptosis-related genes deregulation in patients' PBMCs might be involved in breakdown of immune tolerance and consequently contribute to T1D pathogenesis. Furthermore, HDI-AHSCT modulated the expression of some apoptotic genes towards the levels similar to controls. Possibly, the expression of these apoptotic molecules could be applied as biomarkers of clinical remission of T1D patients treated with HDI-AHSCT therapy.

Indexed as

Gene ExpressionHematopoietic Stem Cell TransplantationAdolescentAdultApoptosisAutoantibodiesbcl-X ProteinDiabetes Mellitus, Type 1Down-RegulationFas Ligand Proteinfas ReceptorFemaleFollow-Up StudiesGlutamate DecarboxylaseHumansImmune ToleranceAutoantibodiesbcl-X ProteinFas Ligand Proteinfas ReceptorGlutamate Decarboxylaseglutamate decarboxylase 2Immunosuppressive AgentsPMAIP1 protein, humanProto-Oncogene Proteins c-bcl-2

Identifiers

PMID22519592
PMCPMC3390481
OpenAlexW1531570128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.